Michael S. Stalvey

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

Margaret Kloster, Steven Mark Rowe, David P. Nichols, Michael S. Stalvey et autres

Rationale: The cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at least one F508del allele, which occurs in at least 85% of people with CF. Objectives: PROMISE is a postapproval study to understand …

us (code pays fourni par la source)

SUN-730 TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia

Jacqueline H. Starrett, Matthias Guillo, Chantal Fayad, Nabil Kaci et autres

Abstract Disclosure: J.H. Starrett: None. C. Lemoine: None. M. Guillo: None. C. Fayad: None. N. Kaci: None. M. Neal: None. E. Pettitt: None. M. Pache: None. Q. Ye: None. M.S. Stalvey: None. R. Charlton: None. R.V. Swanson: None. L. Legeai-Mallet: None. Achondroplasia …

us, fr (code pays fourni par la source)

Cholesterol and triglyceride concentrations following 12–18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor—PROMISE sub-study

Rosara Bass, Michael S. Stalvey, George Marty Solomon, Steven Mark Rowe et autres

• The impact of ETI on cholesterol and triglyceride concentrations, traditional cardiometabolic risk factors, is unknown. • Cholesterol and triglyceride levels were examined prior to and after 12–18 months of ETI. • Total and HDL cholesterol concentrations were higher after 12–18 months …

us (code pays fourni par la source)

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO

Christine L. Chan, Meghan K. Shirley, Darko Stefanovski, Robert Gallop et autres

BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective therapy that improves lung disease in people with cystic fibrosis (pwCF), but its effect on glucose tolerance and insulin secretion is unclear. METHODS: PROMISE is a multicenter prospective, observational study of ETI in pwCF ≥12 …

us (code pays fourni par la source)

658 Longitudinal changes in bone mineral density in adolescents and adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor—results from the PROMISE study

Joseph M. Kindler, Babette S. Zemel, M. Shirley Bezerra, R. Walega et autres

Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis

Traci M. Kazmerski, Olivia M. Stransky, Daniel R. Lavage, Kara S. Hughan et autres

us (code pays fourni par la source)

Growth in Cystic Fibrosis: Is Chloride Transport the Key?

Michael S. Stalvey

Growth restriction has typically been considered one of the clinical aspects of cystic fibrosis (CF). For decades, the focus on children with CF has been on weight gain and body mass, given the correlation with lung function. Only in recent years have …

579 Lipid concentrations after 12 to 18 months of clinically prescribed elexacaftor tezacaftor ivacaftor—PROMISE substudy

Rosara Bass, Michael S. Stalvey, David P. Nichols, Steven Mark Rowe et autres

us (code pays fourni par la source)

581 Glycemia and insulin secretion before and 2 years after elexacaftor-tezacaftor-ivacaftor initiation

Christine L. Chan, Matt Shirley, R. Walega, Steven Mark Rowe et autres

us (code pays fourni par la source)

P312 Provider perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis

Traci M. Kazmerski, Olivia M. Stransky, Daniel R. Lavage, Kara S. Hughan et autres

us (code pays fourni par la source)

Endocrine Complications of Cystic Fibrosis

Andrea Kelly, Brynn E. Marks, Michael S. Stalvey

us (code pays fourni par la source)

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Sarah Jane Schwarzenberg, Phuong T. Vu, M. Skalland, Lucas R. Hoffman et autres

us, ca (code pays fourni par la source)